Palatin receives €5.5 million milestone payment in retinal disease partnership

Palatin Technologies recently announced the submission of a response to the U.S. Food and Drug Administration (FDA) regarding Bremelanotide, the company’s treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA had previously issued a complete response letter (CRL) regarding the New Drug Application (NDA) submitted by Palatin. In the recent press release, the company stated that its response focused on the request for further analysis of existing data and no additional clinical studies were requested by the FDA.

Palatin’s President and CEO, Carl Spana, expressed optimism about the progress made so far and the potential for Bremelanotide to address the unmet need for a treatment for women with HSDD. He emphasized the company’s commitment to working closely with the FDA to address any remaining concerns and move the approval process forward.

The company provided a summary of the response submitted to the FDA, highlighting key points such as the safety and efficacy of Bremelanotide demonstrated in clinical trials. Palatin also noted that the drug had previously received a positive recommendation for approval from the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee.

The press release reiterated that Palatin remains focused on advancing Bremelanotide as a potential treatment option for women with HSDD and is dedicated to addressing any outstanding issues raised by the FDA. The company also stated that it would provide updates on the FDA’s review process as they become available.

In response to the news, industry analysts expressed cautious optimism about the potential approval of Bremelanotide. While there is still uncertainty surrounding the timeline for FDA approval, many believe that Palatin’s response to the FDA’s requests is a step in the right direction. The market reaction to the announcement was generally positive, with Palatin’s stock price showing some gains following the press release.

Overall, Palatin Technologies’ recent submission of a response to the FDA regarding Bremelanotide signals progress in the approval process for this potential treatment for HSDD in premenopausal women. The company’s commitment to addressing the FDA’s requests and providing updates on the status of the drug’s application demonstrates their dedication to bringing this much-needed treatment option to market. With further developments expected in the coming months, stakeholders will be closely monitoring the situation as it unfolds.